Picture of Oncolytics Biotech logo

ONCY — Oncolytics Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Brief: Oncolytics Biotech® Announces Type C FDA Meeting To Discuss Single-Arm Registrational Pathway For Pelareorep In Anal Cancer

April 6 (Reuters) - Oncolytics Biotech Inc ONCY.O:

ONCOLYTICS BIOTECH® ANNOUNCES TYPE C FDA MEETING TO DISCUSS SINGLE-ARM REGISTRATIONAL PATHWAY FOR PELAREOREP IN ANAL CANCER

ONCOLYTICS BIOTECH INC - SCHEDULES TYPE C FDA MEETING ON APRIL 16, 2026 FOR PELAREOREP IN ANAL CANCER

ONCOLYTICS BIOTECH INC - MEETING TO DISCUSS SINGLE-ARM PIVOTAL STUDY OF PELAREOREP IN SECOND-LINE AND LATER SCAC

Source text: ID:nGNX36LGrp

Further company coverage: ONCY.O

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Oncolytics Biotech

See all news